There is 1 paper on laboratory-confirmed respiratory tract infections in aging research: 1 trial in people.
1 paper studies it3 findings
See all 1 papers on laboratory-confirmed respiratory tract infections
- Human trial1
Interventions
2Dactolisib
downin humans1
1 study
Dactolisib
downin humans1
Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (OR 0·601 [90% CI 0·391–0·922]).
“In this analysis we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
Human trial10 mg once daily16 weeks
The lancet. Healthy longevity
Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (phase 2b trial, pooled analysis of parts 1 and 2) (19% vs 28%; OR 0·601 (90% CI 0·391-0·922); p=0·02).
“we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
Human trialphase 2b trial, pooled analysis of parts 1 and 210 mg once daily16 weeks
The lancet. Healthy longevity
RTB101 + everolimus
no changein humans1
1 study
RTB101 + everolimus
no changein humans1
RTB101 + everolimus showed no clear effect on laboratory-confirmed respiratory tract infections in humans.
“RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”
Human trial10 mg plus everolimus 0·1 mg once daily16 weeks
The lancet. Healthy longevity